Financial disclosures of AIDS researchers - 7/14/04 JAMA
While these financial disclosures include many of the doctors
who were involved in AIDS treatment from the very beginning,
it includes nearly all of those who dictate the AIDS standard
of treatment today.
As our esteemed tenured professor of medicine at NYU might say "Plus
Ca Change, Plus C'est la Meme Chose" (The More Things Change, the
More They Stay the Same).
Is this the stuff of good science or has this been an orgy of greed
from the very beginning?
As we look at those who control the world of AIDS treatments on planet
Earth, why don't you be the judge:
JAMA, July 14, 2004 Vol 292, No. 2 251-265
Treatment for Adult 2004 Recommendations International AIDS Society-
USA Panel
Patrick G. Yeni, MD
Scott M. Hammer, MD
Martin S. Hirsch, MD
Michael S. Saag, MD
Mauro Schechter, MD, PhD
Charles C. J. Carpenter, MD
Margaret A. Fischl, MD
Jose M. Gatell, MD, PhD
Brian G. Gazzard, MA, MD
Donna M. Jacobsen, BS
David A. Katzenstein, MD
Julio S. G. Montaner, MD
Douglas D. Richman, MD
Robert T. Schooley, MD
Melanie A. Thompson, MD
Stefano Vella, MD
Paul A. Volberding, MD
Patrick G. Yeni, MD
Dr Yeni has received research grants for site investigator
from GlaxoSmithKline, Bristol- Myers Squibb, Boehringer
Ingelheim, Roche, Tibotec/Virco, and Gilead.
Dr Yeni has received honoraria for advisory positions and lecture
sponsorships from Abbott Laboratories, Bristol-Myers Squibb,
Boehringer Ingelheim, Roche, Tibotec/Virco, and Merck Sharp
and Dohme.
Scott M. Hammer, MD
Dr Hammer has received research grants for site investigator from
Roche, GlaxoSmithKline, and Merck.
Dr Hammer has been a consultant for Bristol-Myers
Squibb, GlaxoSmithKline, Merck, Shionogi, Pfizer, Boehringer
Ingelheim, Shire, Gilead, and Tibotec/ Virco.
Martin S. Hirsch, MD
Dr Hirsch has received research support from Takeda.
Dr Hirsch has been a consultant for Schering Plough, GlaxoSmithKline,
and Bristol-Myers Squibb.
Michael S. Saag, MD
Dr Saag has received research support from Abbott Laboratories,
Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Ortho
Biotech/Johnson&Johnson, Pfizer/Agouron, and Hoffmann- LaRoche.
Dr Saag has been a consultant for Abbott Laboratories, Boeringer
Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline,
OrthoBiotech/Johnson & Johnson, Pfizer/Agouron, Roche,
Schering-Plough, Shire Pharmaceutical, TherapyEdge, Tibotec/ Virco,
Trimeria, Vertex, and ViroLogic.
Dr Saag has received honoraria for positions on the speakers
bureau for Abbott Laboratories, Boeringer Ingelheim, Bristol-Myers
Squibb, Gilead Sciences, GlaxoSmithKline, OrthoBiotech,
Johnson & Johnson, Pfizer, Agouron, Roche, Schering-Plough,
Shire Pharmaceutical, TherapyEdge, Tibotec/Virco, Trimeria,
Vertex, and ViroLogic.
Margaret A. Fischl, MD
Dr Fischl has received research grants from Abbott Laboratories,
Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and
Ortho Biotech.
Dr Fischl has received honoraria for continuing medical education
programs from GlaxoSmithKline.
Dr Fischl has served as an advisor for Agouron Pharmaceuticals and
GlaxoSmithKline.
Brian G. Gazzard, MA, MD
Dr Gazzard has received research grants from Abbott Laboratories,
Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb,
and Johnson &Johnson.
Julio S. G. Montaner, MD
Dr Montaner has received grants from Abbott Laboratories,
Agouron Pharmaceuticals, Shire Biochemical, Boehringer
Ingelheim, Bristol-Myers Squibb, DuPont Pharma, Gilead
Sciences, GlaxoSmithKline, Roche, Kucera Pharmaceutical,
Merck Frosst Laboratories, Pharmacia & Upjohn, and Trimeris.
Dr Montaner has received honoraria for speaking from Abbott
Laboratories, Agouron Pharmaceuticals, Shire Biochemical,
Boehringer Ingelheim, Bristol-Myers Squibb, DuPont Pharma,
Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Kucera
Pharmaceutical, Merck Frosst Laboratories, Pharmacia &
Upjohn, and Trimeris Inc.
Dr Montaner holds 2 US patents, one regarding use of nevirapine
and another regarding pharmacological applications of mitochondrial
DNA assays. Dr Montaner has 2 patent applications that are
pending, one regarding pharmacological applications of
mitochondrial DNA assays and another regarding sepsis.
Robert T. Schooley, MD
Dr Schooley has received grants from GlaxoSmithKline,
Bristol-Myers Squibb, Merck, and Tibotec/Virco.
Dr Schooley has been a consultant for Abbott
Laboratories, Pfizer, Hoffmann-LaRoche, GlaxoSmithKline,
BristolMyers Squibb, Merck, Vertex, ViroLogic, and
Tibotec/Virco.
Melanie A. Thompson, MD
Dr Thompson has received grants from Abbott Laboratories, Agouron/
Pfizer Pharmaceuticals, Boeringer Ingelheim, Bristol-Myers
Squibb, Chiron Corporation, GlaxoSmithKline, Gilead
Sciences, Merck Research Laboratories, Oxo-Chemie, Roche,
Serono, Theratechnologies, Triangle Pharmaceuticals,
Trimeris, and VaxGen.
Dr Thompson has been a consultant for Abbott
Laboratories, Agouron/Pfizer Pharmaceuticals,
GlaxoSmithKline, Gilead Sciences, Serono, and Triangle
Pharmaceuticals.
Dr Thompson has received honoraria for lecture sponsorships and
continuing medical education from Abbott Laboratories,
Agouron/ Pfizer Pharmaceuticals, Boeringer Ingleheim,
Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Roche,
Serono, Triangle Pharmaceuticals, and Trimeris.
Mauro Schechter, MD, PhD
Dr Schechter has received honoraria from Abbott Laboratories,
Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Roche.
Dr Schechter has been a consultant for Abbott Laboratories,
BristolMyers Squibb, GlaxoSmithKline, Merck, and Roche.
Jose M. Gatell, MD, PhD
Dr Gatell has served in advisory positions for Roche, Bristol-Myers
Squibb, Merck Sharp and Dohme, GlaxoSmithKline, Gilead,
Boehringer Ingelheim, Abbott Laboratories, Tibotec/ Virco.
Brian G. Gazzard, MA, MD
Dr Gazzard has received lectureship fees from Abbott Laboratories,
Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb,
and Johnson & Johnson.
David A. Katzenstein, MD
Dr Katzenstein has held advisory positions at Boehringer Ingelheim,
Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck,
ViroLogic, Visible Genetics, and the Doris Duke Charitable Trust.
Dr Katzenstein holds a US patent for polymerase chain reaction
assays monitoring antiviral therapy and making therapeutic
decisions in the treatment of AIDS.
Stefano Vella, MD
Dr Vella has received lecture sponsorship for
satellite symposia and continuing medical education programs
from Merck, Agouron, Gilead, Boehringer Ingelheim, and
Roche.
Paul A. Volberding, MD
Dr Volberding has received honoraria from Gilead,
Bristol-Myers Squibb, GlaxoSmithKline, and Boehringer
Ingelheim.
Dr Volberding has been a consultant for Pfizer, Bristol-Myers
Squibb, and Shire.
Douglas D. Richman, MD
Dr Richman has been a consultant for Abbott Laboratories,
Bristol-Myers Squibb, Chiron, Gilead, GlaxoSmithKline,
Merck, Novirio, Pfizer, Roche, Takeda, Triangle, and
ViroLogic.
